Stage 3 NSCLC generally represents locally advanced disease with regional lymph node involvement and is subdivided into IIIA, IIIB, and IIIC, each with different management pathways. Some Stage 3 cases are resectable, allowing a curative-intent approach that may include surgery combined with chemo-radiation and systemic therapy. Unresectable Stage 3 is often treated with concurrent chemoradiation, and in suitable patients, consolidation immunotherapy has become a key component. Therefore, Stage 3 is not automatically “terminal.” With accurate staging and coordinated multidisciplinary care, many patients can achieve long-term control and, in selected cases, curative outcomes. The decision hinges on precise imaging, pathology, and team-based planning.